UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Outcome and follow-up of diethylstilbestrol (DES) exposed individuals

Author
Elizabeth Hatch, PhD
Section Editors
Susan M Ramin, MD
Barbara Goff, MD
Deputy Editor
Sandy J Falk, MD, FACOG

INTRODUCTION

Diethylstilbestrol (DES) is a nonsteroidal estrogen first synthesized in 1938. It readily crosses the placenta. Exposure to DES during a critical period of organogenesis disorganizes the developing uterine muscle layers; causes maldevelopment of the uterotubal junction; and prevents stratification of the vaginal epithelium and resorption of vaginal glands, resulting in vaginal adenosis. In murine studies, the mechanism for DES-induced adenosis is blocked expression of Trp63 in Müllerian duct epithelium at epithelial estrogen receptor alpha [1]. DES has also been shown to alter normal programming of the gene families Hox and Wnt, which affect differentiation of the reproductive tract [2-6].

DES was initially used for postpartum lactation suppression and treatment of postmenopausal symptoms, but quickly became an accepted intervention for prevention of miscarriage, premature birth, and other pregnancy problems. It is estimated that five million pregnant women worldwide received DES to improve pregnancy outcome. Although clinical trials in the 1950s demonstrated that it was ineffective for prevention of adverse pregnancy outcomes [7], it remained in use until 1971 in the United States and until the early 1980s in some other countries. In 1971, in-utero exposure to DES was linked to the occurrence of vaginal clear cell adenocarcinoma in female offspring [8], which prompted the US Food and Drug Administration (FDA) to advise against its use in pregnancy [9]. Subsequently, other health effects, such as pregnancy complications and male genitourinary tract abnormalities, were also linked to in-utero DES exposure. DES is no longer commercially available for human use in North America.

DES remains the only firmly established transplacental carcinogen in humans. Because of this risk, it is important to continue to monitor exposed offspring and their mothers for long-term health effects. DES is also important as the model agent for endocrine disrupting chemicals and their effects on fetal development and adult health [10,11]. Aberrant DNA methylation has been proposed as a molecular mechanism whereby endocrine disruptors such as DES regulate developmental programming [12].

WOMEN WHO RECEIVED DES DURING PREGNANCY (DES MOTHERS)

Breast cancer risk — There appears to be a slightly increased incidence of breast cancer among women who were prescribed DES during pregnancy (DES mothers) [13-18]. The largest and most comprehensive study on this topic compared long-term cancer risk in a database of 3844 women prescribed DES during pregnancy to an unexposed comparison group of 3716 women [14]. Women who took DES had a small increased risk of breast cancer (relative risk [RR] 1.27, 95% CI 1.07-1.52); looked at in another way, their lifetime risk of breast cancer increased from 1 in 8 (about 12 percent) to 1 in 6 (about 17 percent). There was no evidence of an interaction between the use of postmenopausal hormone therapy and DES in relation to breast cancer risk, and the risk did not increase over time. The higher risk did not appear to be due to inherent characteristics of the women who were given DES (ie, women with pregnancy problems) [16].

Other cancers — Women who were prescribed DES during pregnancy are not at increased risk of ovarian or endometrial cancer [13-18].

                                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Sep 17 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Kurita T, Mills AA, Cunha GR. Roles of p63 in the diethylstilbestrol-induced cervicovaginal adenosis. Development 2004; 131:1639.
  2. Maydl R, Newbold RR, Metzler M, McLachlan JA. Diethylstilbestrol metabolism by the fetal genital tract. Endocrinology 1983; 113:146.
  3. Miller C, Degenhardt K, Sassoon DA. Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis. Nat Genet 1998; 20:228.
  4. Pavlova A, Boutin E, Cunha G, Sassoon D. Msx1 (Hox-7.1) in the adult mouse uterus: cellular interactions underlying regulation of expression. Development 1994; 120:335.
  5. Taylor HS, Vanden Heuvel GB, Igarashi P. A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes. Biol Reprod 1997; 57:1338.
  6. Woodruff TJ, Carlson A, Schwartz JM, Giudice LC. Proceedings of the Summit on Environmental Challenges to Reproductive Health and Fertility: executive summary. Fertil Steril 2008; 89:281.
  7. Bamigboye AA, Morris J. Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes. Cochrane Database Syst Rev 2003; :CD004353.
  8. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284:878.
  9. FDA Drug Bulletin:Diethylstilbestrol contraindicated in pregnancy. US Department of Health, Education, and Welfare. Washington, DC, 1971.
  10. Newbold RR, Padilla-Banks E, Jefferson WN. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. Endocrinology 2006; 147:S11.
  11. Ma L. Endocrine disruptors in female reproductive tract development and carcinogenesis. Trends Endocrinol Metab 2009; 20:357.
  12. Bromer JG, Wu J, Zhou Y, Taylor HS. Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: an epigenetic mechanism for altered developmental programming. Endocrinology 2009; 150:3376.
  13. Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med 1995; 122:778.
  14. Titus-Ernstoff L, Hatch EE, Hoover RN, et al. Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. Br J Cancer 2001; 84:126.
  15. Hadjimichael OC, Meigs JW, Falcier FW, et al. Cancer risk among women exposed to exogenous estrogens during pregnancy. J Natl Cancer Inst 1984; 73:831.
  16. Colton T, Greenberg ER, Noller K, et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. Further follow-up. JAMA 1993; 269:2096.
  17. Greenberg ER, Barnes AB, Resseguie L, et al. Breast cancer in mothers given diethylstilbestrol in pregnancy. N Engl J Med 1984; 311:1393.
  18. Calle EE, Mervis CA, Thun MJ, et al. Diethylstilbestrol and risk of fatal breast cancer in a prospective cohort of US women. Am J Epidemiol 1996; 144:645.
  19. Titus-Ernstoff L, Troisi R, Hatch EE, et al. Mortality in women given diethylstilbestrol during pregnancy. Br J Cancer 2006; 95:107.
  20. Troisi R, Hatch EE, Titus-Ernstoff L, et al. Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer 2007; 121:356.
  21. Melnick S, Cole P, Anderson D, Herbst A. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med 1987; 316:514.
  22. Laronda MM, Unno K, Butler LM, Kurita T. The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero. Differentiation 2012; 84:252.
  23. Registry for Research on Hormonal Transplacental Carcinogenesis (obgyn.bsd.uchicago.edu/registry.html). Accessed October 5, 2010
  24. Hanselaar A, van Loosbroek M, Schuurbiers O, et al. Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. Cancer 1997; 79:2229.
  25. Verloop J, van Leeuwen FE, Helmerhorst TJ, et al. Cancer risk in DES daughters. Cancer Causes Control 2010; 21:999.
  26. Waggoner SE, Anderson SM, Van Eyck S, et al. Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix. Obstet Gynecol 1994; 84:404.
  27. Herbst AL, Anderson D. Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol. Semin Surg Oncol 1990; 6:343.
  28. Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med 2011; 365:1304.
  29. Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol 2007; 8:1088.
  30. Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:1509.
  31. Hornsby PP, Wilcox AJ, Weinberg CR, Herbst AL. Effects on the menstrual cycle of in utero exposure to diethylstilbestrol. Am J Obstet Gynecol 1994; 170:709.
  32. Kaufman RH, Adam E, Noller K, et al. Upper genital tract changes and infertility in diethylstilbestrol-exposed women. Am J Obstet Gynecol 1986; 154:1312.
  33. Robboy SJ, Kaufman RH, Prat J, et al. Pathologic findings in young women enrolled in the National Cooperative Diethylstilbestrol Adenosis (DESAD) project. Obstet Gynecol 1979; 53:309.
  34. Noller KL, Townsend DE, Kaufman RH, et al. Maturation of vaginal and cervical epithelium in women exposed in utero to diethylstilbestrol (DESAD Project). Am J Obstet Gynecol 1983; 146:279.
  35. Hatch EE, Troisi R, Wise LA, et al. Age at natural menopause in women exposed to diethylstilbestrol in utero. Am J Epidemiol 2006; 164:682.
  36. Palmer JR, Hatch EE, Rao RS, et al. Infertility among women exposed prenatally to diethylstilbestrol. Am J Epidemiol 2001; 154:316.
  37. Missmer SA, Hankinson SE, Spiegelman D, et al. In utero exposures and the incidence of endometriosis. Fertil Steril 2004; 82:1501.
  38. DeCherney AH, Cholst I, Naftolin F. Structure and function of the fallopian tubes following exposure to diethylstilbestrol (DES) during gestation. Fertil Steril 1981; 36:741.
  39. Kaufman RH, Adam E, Hatch EE, et al. Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring. Obstet Gynecol 2000; 96:483.
  40. Swan, SH. Pregnancy outcome in DES daughters. In: Giusti, RM(ed). Report of the NIH Workshop on Long-Term Effects of Exposure to Diethylstilbestrol (DES). US Department of Health and Human Services, Public Health Service, National Institutes of health, Washington, DC 1992, p. 42.
  41. Levine RU, Berkowitz KM. Conservative management and pregnancy outcome in diethylstilbestrol-exposed women with and without gross genital tract abnormalities. Am J Obstet Gynecol 1993; 169:1125.
  42. Wise LA, Palmer JR, Hatch EE, et al. Secondary sex ratio among women exposed to diethylstilbestrol in utero. Environ Health Perspect 2007; 115:1314.
  43. Verloop J, Rookus MA, van Leeuwen FE. Prevalence of gynecologic cancer in women exposed to diethylstilbestrol in utero. N Engl J Med 2000; 342:1838.
  44. Noller KL, Blair PB, O'Brien PC, et al. Increased occurrence of autoimmune disease among women exposed in utero to diethylstilbestrol. Fertil Steril 1988; 49:1080.
  45. Baird DD, Wilcox AJ, Herbst AL. Self-reported allergy, infection, and autoimmune diseases among men and women exposed in utero to diethylstilbestrol. J Clin Epidemiol 1996; 49:263.
  46. Strohsnitter WC, Noller KL, Troisi R, et al. Autoimmune disease incidence among women prenatally exposed to diethylstilbestrol. J Rheumatol 2010; 37:2167.
  47. Luster MI, Faith RE, McLachlan JA. Alterations of the antibody response following in utero exposure to diethylstilbestrol. Bull Environ Contam Toxicol 1978; 20:433.
  48. Troisi R, Hyer M, Hatch EE, et al. Medical conditions among adult offspring prenatally exposed to diethylstilbestrol. Epidemiology 2013; 24:430.
  49. Kebir O, Krebs MO. Diethylstilbestrol and risk of psychiatric disorders: a critical review and new insights. World J Biol Psychiatry 2012; 13:84.
  50. Titus-Ernstoff L, Perez K, Hatch EE, et al. Psychosexual characteristics of men and women exposed prenatally to diethylstilbestrol. Epidemiology 2003; 14:155.
  51. Wise LA, Palmer JR, Rowlings K, et al. Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure. Obstet Gynecol 2005; 105:167.
  52. Mahalingaiah S, Hart JE, Wise LA, et al. Prenatal diethylstilbestrol exposure and risk of uterine leiomyomata in the Nurses' Health Study II. Am J Epidemiol 2014; 179:186.
  53. Hao CJ, Cheng XJ, Xia HF, Ma X. The endocrine disruptor diethylstilbestrol induces adipocyte differentiation and promotes obesity in mice. Toxicol Appl Pharmacol 2012; 263:102.
  54. Newbold RR, Padilla-Banks E, Jefferson WN. Environmental estrogens and obesity. Mol Cell Endocrinol 2009; 304:84.
  55. Hatch EE, Troisi R, Palmer JR, et al. Prenatal diethylstilbestrol exposure and risk of obesity in adult women. J Dev Orig Health Dis 2015; 6:201.
  56. Palmer JR, Herbst AL, Noller KL, et al. Urogenital abnormalities in men exposed to diethylstilbestrol in utero: a cohort study. Environ Health 2009; 8:37.
  57. Wilcox AJ, Baird DD, Weinberg CR, et al. Fertility in men exposed prenatally to diethylstilbestrol. N Engl J Med 1995; 332:1411.
  58. Leary FJ, Resseguie LJ, Kurland LT, et al. Males exposed in utero to diethylstilbestrol. JAMA 1984; 252:2984.
  59. Vessey MP, Fairweather DV, Norman-Smith B, Buckley J. A randomized double-blind controlled trial of the value of stilboestrol therapy in pregnancy: long-term follow-up of mothers and their offspring. Br J Obstet Gynaecol 1983; 90:1007.
  60. Perez KM, Titus-Ernstoff L, Hatch EE, et al. Reproductive outcomes in men with prenatal exposure to diethylstilbestrol. Fertil Steril 2005; 84:1649.
  61. Wise LA, Titus-Ernstoff L, Palmer JR, et al. Time to pregnancy and secondary sex ratio in men exposed prenatally to diethylstilbestrol. Am J Epidemiol 2007; 166:765.
  62. Bibbo M, Gill WB, Azizi F, et al. Follow-up study of male and female offspring of DES-exposed mothers. Obstet Gynecol 1977; 49:1.
  63. Andonian RW, Kessler R. Transplacental exposure to diethylstilbestrol in men. Urology 1979; 13:276.
  64. Depue RH, Pike MC, Henderson BE. Estrogen exposure during gestation and risk of testicular cancer. J Natl Cancer Inst 1983; 71:1151.
  65. Moss, A, Osmond, D, Bacchetti, P, et al. Hormonal risk factors in testicular cancer: a case-control study. Am J Epidemiol 1986;124:39.
  66. Weir HK, Marrett LD, Kreiger N, et al. Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer. Int J Cancer 2000; 87:438.
  67. Henderson BE, Benton B, Jing J, et al. Risk factors for cancer of the testis in young men. Int J Cancer 1979; 23:598.
  68. Brown LM, Pottern LM, Hoover RN. Prenatal and perinatal risk factors for testicular cancer. Cancer Res 1986; 46:4812.
  69. Gershman ST, Stolley PD. A case-control study of testicular cancer using Connecticut tumour registry data. Int J Epidemiol 1988; 17:738.
  70. Strohsnitter WC, Noller KL, Hoover RN, et al. Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst 2001; 93:545.
  71. Schottenfeld D, Warshauer ME, Sherlock S, et al. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980; 112:232.
  72. Newbold RR, Bullock BC, McLachlan JA. Testicular tumors in mice exposed in utero to diethylstilbestrol. J Urol 1987; 138:1446.
  73. Kaufman RH, Adam E. Findings in female offspring of women exposed in utero to diethylstilbestrol. Obstet Gynecol 2002; 99:197.
  74. Titus-Ernstoff L, Troisi R, Hatch EE, et al. Menstrual and reproductive characteristics of women whose mothers were exposed in utero to diethylstilbestrol (DES). Int J Epidemiol 2006; 35:862.
  75. Klip H, Verloop J, van Gool JD, et al. Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study. Lancet 2002; 359:1102.
  76. Pons JC, Papiernik E, Billon A, et al. Hypospadias in sons of women exposed to diethylstilbestrol in utero. Prenat Diagn 2005; 25:418.
  77. Palmer JR, Wise LA, Robboy SJ, et al. Hypospadias in sons of women exposed to diethylstilbestrol in utero. Epidemiology 2005; 16:583.
  78. Felix JF, Steegers-Theunissen RP, de Walle HE, et al. Esophageal atresia and tracheoesophageal fistula in children of women exposed to diethylstilbestrol in utero. Am J Obstet Gynecol 2007; 197:38.e1.
  79. Titus-Ernstoff L, Troisi R, Hatch EE, et al. Birth defects in the sons and daughters of women who were exposed in utero to diethylstilbestrol (DES). Int J Androl 2010; 33:377.
  80. Titus-Ernstoff L, Troisi R, Hatch EE, et al. Offspring of women exposed in utero to diethylstilbestrol (DES): a preliminary report of benign and malignant pathology in the third generation. Epidemiology 2008; 19:251.
  81. Newbold RR, Hanson RB, Jefferson WN, et al. Increased tumors but uncompromised fertility in the female descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis 1998; 19:1655.
  82. Newbold RR, Hanson RB, Jefferson WN, et al. Proliferative lesions and reproductive tract tumors in male descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis 2000; 21:1355.
  83. Palmer JR, Anderson D, Helmrich SP, Herbst AL. Risk factors for diethylstilbestrol-associated clear cell adenocarcinoma. Obstet Gynecol 2000; 95:814.
  84. http://www.cancer.org/Cancer/CancerCauses/OtherCarcinogens/MedicalTreatments/des-exposure (Accessed on June 14, 2012).
  85. www.cancer.gov (Accessed on June 14, 2012).
  86. CDC. DES update: health care providers. Information to identify and manage DES patients http://www.cdc.gov/des/hcp/information/women/index.html (Accessed on June 20, 2012).
  87. Clinician Information: DES Daughters - Women Exposed in Utero www.cancer.gov/cancertopics/causes/des/daughters-exposed-to-des (Accessed on July 11, 2012).